Salgueiro M, et al. - Considering that long-acting injectable (LAI) antipsychotics could be a favorable option of treatment and have some advantages over oral medications, researchers reviewed the published data on the use of LAI formulation of second-generation antipsychotics (SGA) in first-episode psychosis (FEP). The inclusion criteria were fulfilled by 5 studies evaluating the effect of LAI risperidone in FEP patients. The analysis suggests the treatment with LAI SGAs as significantly advantageous over oral antipsychotics to FEP patients, especially to improve the adherence to medication and prevent the worsening of symptoms, the relapse, and rehospitalization associated with the discontinuation of treatment.